Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.48 |
| ▸ | MTTP | P55157 | 2/20 | 0.47 |
| ▸ | APOB | P04114 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497909 | 0.93 | SMO (0.52) | SMOTRPV1MTTPAPOBNR3C1 | |
| SCHEMBL6489227 | 0.93 | CTNNB1 (0.48) | CTNNB1TCF7L2 | |
| SCHEMBL6501149 | 0.92 | TRPV1 (0.50) | SMOTRPV1MTTPAPOB | |
| SCHEMBL6495258 | 0.92 | SMO (0.48) | SMOTRPV1MTTPAPOBNR3C1 | |
| SCHEMBL6498069 | 0.91 | HDAC7 (0.49) | SMOCTNNB1TCF7L2 | |
| SCHEMBL6802784 | 0.90 | SMO (0.51) | SMOTRPV1MTTPAPOBNR3C1 | |
| SCHEMBL6497765 | 0.90 | SMO (0.51) | SMOTRPV1MTTPAPOBNR3C1 | |
| SCHEMBL6501182 | 0.90 | SMO (0.53) | SMOTRPV1NR3C1EGLN1 | |
| SCHEMBL6488546 | 0.90 | CTNNB1 (0.54) | CTNNB1TCF7L2 | |
| SCHEMBL6502553 | 0.89 | SMO (0.51) | SMOTRPV1MTTPAPOBNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | claimed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMO 2580/4885TRPV1 2245/4885MTTP 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.